Cargando…
The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs
BACKGROUNDS: Recent clinical trials have shown that immune-checkpoint blockade yields remarkable response in a subset of non–small cell lung cancer (NSCLC) patients. However, few studies directly focus on the association between epidermal growth factor receptor (EGFR) mutational status and programme...
Autores principales: | Tang, Yanna, Fang, Wenfeng, Zhang, Yaxiong, Hong, Shaodong, Kang, Shiyang, Yan, Yue, Chen, Nan, Zhan, Jianhua, He, Xiaobo, Qin, Tao, Li, Ge, Tang, Wenyi, Peng, Peijian, Zhang, Li |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4546461/ https://www.ncbi.nlm.nih.gov/pubmed/25895031 |
Ejemplares similares
-
Influence of PD‐L1 expression on the efficacy of
EGFR‐TKIs in
EGFR
‐mutant non‐small cell lung cancer
por: Lei, Si‐Yu, et al.
Publicado: (2023) -
PD-L1 expression and its effect on clinical outcomes of EGFR-mutant NSCLC patients treated with EGFR-TKIs
por: Bai, Yuchen, et al.
Publicado: (2018) -
Patients With Short PFS to EGFR-TKIs Predicted Better Response to Subsequent Anti-PD-1/PD-L1 Based Immunotherapy in EGFR Common Mutation NSCLC
por: Liu, Sangtian, et al.
Publicado: (2021) -
Soluble PD-L1 as a Predictor of the Response to EGFR-TKIs in Non-small Cell Lung Cancer Patients With EGFR Mutations
por: Jia, Yijun, et al.
Publicado: (2020) -
The efficacy of anti-PD-1/PD-L1 therapy and its comparison with EGFR-TKIs for advanced non-small-cell lung cancer
por: Sheng, Zhixin, et al.
Publicado: (2017)